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Abstract Effects of amino acid substitutions in the first ex- 
tracellular loop region of the ~- and p-opioid receptors were 
examined. Substitution of lysine-108 of the fi-receptor (~K108) 
with asparagine improved affinity to [D-Ala2,MePbe4,Gly-olSlenk 
ephalin (DAGO), a p-selective peptide agonist, to be comparable 
with that of the p-receptor. On the other hand, replacement of 
raN127 with lysine decreased the affinity to DAGO by ~ 15-fold. 
These results suggest hat dK108 and mN127, which correspond 
to each other in the aligned amino acid sequences, mainly deter- 
mine the difference in DAGO binding affinity between the ~- and 
p-receptors. 
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1. Introduction 
Opioid analgesics interact specifically with the opioid recep- 
tor present in the nervous ystem to produce various cellular 
responses through the action of the guanine nucleotide-binding 
regulatory proteins (G-proteins). Pharmacologically, the opioid 
receptor has been classified into at least three types (8, p and 
x), on the basis of the difference in binding affinities to opioid 
ligands [1,2]. The ~-receptor is characterized by high-affinity 
binding of a peptide agonist [D-penicillamine2,D-penicillam - 
ineS]enkephalin (DPDPE), while the p-receptor has been shown 
to bind a peptide agonist [D-Ala2,MePhe4,Gly-olS]enk ephalin 
(DAGO) and an alkaloid agonist morphine with high affinity 
[3]. 
Recently, the cDNAs encoding three types of the opioid 
receptor (8,/.t and x) have been cloned. Analysis of the primary 
structures deduced from the nucleotide sequences of the 
cDNAs revealed that the three opioid receptors possess charac- 
teristic structural features of the G-protein-coupled receptor 
family, including the presence of seven putative transmembrane 
segments, and have high amino acid sequence identities (-60%) 
to each other [4]. Furthermore, attempts have been made to 
understand the structural basis of the ligand selectivity of the 
opioid receptors, by means of site-directed mutagenesis and 
cDNA expression [5-13]. Previously, we have reported that the 
region extending from the intracellular loop region (ICL-I to 
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the amino-terminal half of the transmembrane segment (TM)- 
III of the p-opioid receptor contains the major determinant for 
the high-affinity binding of the p-selective peptide agonist 
DAGO [10]. In contrast, he major binding determinant for the 
8-selective peptide DPDPE and that for the p-selective alkaloid 
morphine were shown to exist within the region spanning TM 
V-VII. 
In this investigation, to identify the amino acid residues in- 
volved in determination f the difference in DAGO binding 
affinity between the ~- and the p-opioid receptors, we examined 
agonist binding properties of the receptors in which the amino 
acid residues divergent between the 8- and the p-receptors 
around the extracellular loop region (ECL)-I were mutated. 
The results obtained indicate that the difference in DAGO 
binding affinity is mainly determined by the difference of one 
amino acid residue in ECL-I in the aligned amino acid se- 
quences (8K108 and pN127; amino acid residues followed by 
residue numbers). Furthermore, pG131 was suggested to be 
located near the agonist binding site of the p-receptor. 
2. Materials and methods 
2.1. Construction of expression plasmids for mutant receptors 
cDNAs encoding the rat g~- and/.t-opioid receptors [14] were cloned 
into bacteriophage M 13mp 18. Mutations were introduced by oligonu- 
cleotide-directed mutagenesis (Amersham), and confirmed by sequenc- 
ing the single-stranded DNAs. The entire protein-coding sequences of 
the mutant cDNAs were excised from the double-stranded DNAs, and 
inserted into the HindlII site of an expression vector pKCRH2 [15] in 
the same orientation with respect to SV40 early promoter. Expression 
plasmids for the wild-type rat ~- and/g-opioid receptors were described 
previously [10]. 
2.2. Transfection and ligand-binding assay 
COS-7 cells were maintained inDulbecco's modified Eagle's medium 
supplemented with 5% fetal calf serum at 37°C in a humidified atmos- 
phere of 95% air/5% CO2 and transfected with expression plasmids for 
the wild-type or mutant receptors by the calcium phosphate method 
[16]. 
After 72-h incubation at 37°C, cells were washed with phosphate- 
buffered saline, harvested and stored at -80°C before use. Frozen cells 
were thawed and homogenized with a Dounce homogenizer in 50 mM 
Tris-HC1, pH 7.5. The homogenate was centrifuged at1,000 xg for 10 
rain and the precipitate suspended in the same buffer, homogenized and 
centrifuged at 1,000 xg for 10 rain. The two supernatants were com- 
bined and centrifuged at 20,000 x g for 30 rain. The pellet was sus- 
pended in the same buffer and used for binding assays. [3H]Ethylketo- 
cyclazocine (EKC) or [3H]DAGO binding reaction was performed with 
membrane preparations (20-50 pg of protein) in 0.2 ml of 50 mM 
Tris-HCl, pH 7.5, at 37°C for 1 h. After incubation, the samples were 
collected on GF/B filters (Whatman) and washed with 10 ml of 50 mM 
Tris-HC1, pH 7.5. The filters were then counted for radioactivity. K~ 
values for DAGO, DPDPE and morphine were obtained by displace- 
ment of [3H]EKC binding by unlabeled ligands and calculation by the 
equation Ki = IC5J(1 + L/Kd*) [17], where ICs0 is concentration f the 
unlabeled ligand producing a 50% reduction in the [3H]EKC binding, 
L is concentration f [3H]EKC, and Kd* is the apparent dissociation 
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constant for [3H]EKC estimated by Scatchard analysis. Kd values for 
DAGO were determined by Scatchard analysis using [3H]DAGO. All 
determinations were performed in duplicate. 
3. Results 
Previously, we have demonstrated that the difference in 
DAGO binding affinity between the 6- and the H-receptors is 
mainly determined by the amino acid sequences of the region 
spanning from ICL-I to the amino-terminal half of TM-II I  [10] 
(Fig. 1). The amino acid sequence of this region is well con- 
served between the 6- and the/~-receptors [14]. In fact, amino 
acid residues are identical at 48 of 56 positions in this region 
of these receptors, and 7 of 8 non-identical residues are clus- 
tered around ECL-I (Fig. 1B). Since it is unlikely that amino 
acid residues in the cytoplasmic region directly contributes to 
ligand binding, we expected the non-identical mino acid resi- 
dues around ECL-I to be chiefly involved in determining the 
difference in DAGO binding affinity of these receptors. To find 
out the amino acid residues involved in determining DAGO 
binding affinity, mutant receptors, in which the amino acid 
residues around ECL-I divergent between the ~- and/l-recep- 
tors were changed, were expressed transiently in COS-7 cells 
and tested for their agonist binding properties using crude 
membrane preparations. All mutant receptors bound EKC 
with Kd values comparable with those of the wild-type 6- and 
/~-receptors, ranging from 1.7 to 12.0 nM (Table 1), suggesting 
that global structural deterioration was not induced by the 
mutations. Binding affinities to DAGO, DPDPE and morphine 
were estimated by displacement of [3H]EKC binding. 
Substitutions of six of the seven non-conserved residues 
around ECL-I of the 6-receptor with the corresponding resi- 
dues of the/.t-receptor (6AI07V, ~El l2G,  6El18T, 6Ll19I, 
~A1231 and ~L125I; amino acid residues in the wild-type and 
the mutant preceding and following the number of the altered 
residue, respectively) (Fig. 1B) affected little the binding affini- 
ties to DAGO, DPDPE and morphine (Table 1). In contrast, 
replacement of ~K108 with the corresponding residue of the 
/~-receptor (~K108N) caused drastic change in DAGO binding 
affinitiy (Table 1; Fig. 2A). The K i value for DAGO of 6K108N 
was 41 + 4 nM (mean + S.E.M.; n = 5), comparable with that 
of the wild-type/t-receptor and more than 30-fold lower than 
that of the ~-receptor. The binding affinities to DPDPE and 
morphine were also affected by this replacement (Table 1; Fig. 
2B,C), but the changes in Ki values were much smaller than in 
the case of DAGO. To assess the role of amino acid residue-108 
of the 6-receptor in defining agonist binding property, mutant 
receptors in which ~K108 was replaced with arginine, aspartic 
acid or alanine were tested (Table 1; Fig. 2). The affinity to 
DAGO of 6K108R was comparable with that of the wild-type 
~-receptor, whereas the K~ values for DAGO of ~K108D and 
~K 108A were comparable with that of 6K 108N and 15~0-fold 
lower than that of the wild-type 6-receptor. These mutations 
caused small changes in the affinities to DPDPE and morphine. 
Next, we analyzed effects of mutations around ECL-I of the 
/~-receptor. Replacement of five of the seven divergent amino 
acid residues of the H-receptor with corresponding residues of 
the 6-receptor (HV 126A, JzT 137E, HI 138L, HI 142A and HI 144L) 
(Fig. 1B) did not significantly affect binding affinities to 
DAGO, DPDPE and morphine (Table 1). The mutation 
/IN127K, that is the reciprocal mutation of dK108N (see 
above), increased the K i value for DAGO - 15-fold (Table 1; Fig. 
2A). The ~ value for morphine was-2.5-fold increased, and that 
for DPDPE was ~ 3-fold decreased by this substitution (Table 1; 
Fig. 2B,C). Replacement of/.tG131 with the corresponding 
amino acid residue (HG131 E) dramatically changed the agonist 
Table 1 
Agonist-binding properties of the mutant receptors 
Kd (nM) K~ (nM) 
Receptor EKC DAGO DPDPE Morphine 
8.6 + 1.6 (4) 1,300 + 300 (4) 32 + 6 (4) 330 + 60 (4) 
/1 4.6 + 0.3 (4) 17 + 5 (3) 10,420 _+ 2,030 (6) 32 + 6 (4) 
d~A107V 6.3 + 1.7 (3) 990 + 130 (3) 19 + 6 (3) 350 + 10 (3) 
~K108N 3.2 _+ 0.6 (3) 41 + 4 (5) 80 + 3 (3) 140 + 10 (4) 
6K108R 5.2 + 0.3 (3) 810 _+ 110 (3) 153 + 10 (3) 470 + 30 (3) 
~K108D 3.1 +0.3 (3) 60_+ 13 (3) 102_+4 (3) 110+5 (3) 
~K108A 3.4 _+ 0.1 (3) 90 + 6 (3) 137 _+ 5 (3) 100 + 7 (3) 
~E112G 8.7 _+ 0.8 (3) 1,330 _+ 220 (4) 32 _+ 2 (3) 440 _+ 10 (4) 
d~E118T 7.5 + 1.1 (3) 1,890 + 420 (4) 33 _+ 5 (3) 450 + 10 (4) 
d~L1191 6.3 + 0.6 (3) 1,050 -+ 80 (3) 15 + 2 (3) 320 + 10 (3) 
~A123I 6.8 -+ 1.1 (3) 1,280 + 0 (3) 25 -+ 1 (3) 400 _+ 20 (3) 
~L1251 8.9 + 1.9 (3) 1,140 + 40 (3) 14 _+ 5 (3) 550 _+ 30 (3) 
/~V126A 4.8 _+ 0.9 (3) 23 _+ 6 (4) 14,020 _+ 1,110 (3) 37 + 2 (3) 
,uN127K 8.3 _+ 0.7 (3) 270 _+ 50 (5) 3,660 _+ 270 (6) 81 _+ 14 (5) 
/tGI31E 12.0 _+ 1.0 (3) 2,380 _+ 410 (5) 160 _+ 30 (6) 1,220 _+ 380 (5) 
/~G131A 3.8 + 0.2 (3) 24 -+ 1 (3) 8,080 _+ 700 (4) 45 -.% 2 (3) 
/.tT137E 4.1 _+ 0.6 (3) 35 + 8 (5) 6,540 _+ 1,370 (3) 43 _+ 6 (5) 
/~I138L 3.8 _+ 0.4 (3) 15 _+ 2 (4) 8,390 _+ 320 (3) 25 _+ 2 (3) 
/~I142A 3.1 -+ 0.2 (3) 17 -+ 3 (4) 8,440 + 560 (3) 19 _+ 4 (3) 
HII44L 1.7 -+ 0.1 (3) 24 + 3 (4) 13,120 + 1,420 (3) 19 -+ 2 (3) 
Data are given as means + S.E.M.; numbers in parentheses refer to the number of experiments. K d for EKC was estimated by Scatchard analysis 
using [3H]EKC. K~ for DAGO, DPDPE and morphine were determined by measuring displacement of [3H]EKC binding by unlabeled ligands (see 
Figs. 2, 3). 
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Fig. 1. Topographical model and sequence alignment of the opioid receptor. (A) Proposed two-dimensional structure and amino acid sequence of 
the rat It-opioid receptor. The model is based on the amino acid sequence of the rat It-receptor deduced from the cDNA sequence [14]. The amino 
acid residues (one-letter code) conserved between the aligned sequences ofthe ~- and It-receptors are indicated by closed circles, and divergent ones 
by open circles. (B) Alignment of the amino acid sequences ofthe rat 6- andit-opioid receptors in the region spanning from ICL-I to the amino-terminal 
half of TM-III, which were previously shown to contain the major determinant for the difference in DAGO binding affinity [10]. Amino acid residues 
(one-letter code) divergent between the ~- and It-receptors are boxed and numbered [14]. The positions of the predicted transmembrane s gments 
(TM-II and -III) are indicated by bars. 
binding property, in contrast with the reciprocal mutation 
~El l2G (Table 1; Fig. 3). The Ki values for DAGO and mor- 
phine were increased - 140-fold and ~40-fold, respectively, tobe 
even higher than those of the wild-type ~-receptor. The K~ value 
for DPDPE was decreased more than 60-fold, to be only ~ 5-fold 
higher than that of the wild-type ~-receptor. However, the 
mutation/IG131A did not significantly change the binding af- 
finities to agonists (Table 1; Fig. 3). 
Scatchard analysis with [3H]DAGO demonstrated that the 
Kd value for DAGO of dK108N was 2.7 + 0.2 nM (n = 3), 
which was comparable with that of the wild-type/l-receptor 
(1.7 + 0.2 nM; n = 3) (Fig. 4). The K d values of the wild-type 
~-receptor, ~E l l2G, / IN I27K and ~tG131E could not be ob- 
tained, because they poorly bound [3H]DAGO, although all of 
them were shown to bind [3H]EKC with high affinities (Table 
1). These results are consistent with the data obtained by dis- 
placement of [3H]EKC binding, indicating that ~K108 and 
~tN127 are important in determining the difference in DAGO 
binding affinity, and that the DAGO binding affinity is im- 
paired by the mutation gtG131E but not significantly changed 
by the reciprocal mutation ~E112G. 
4. Discussion 
In this investigation, we have attempted to identify amino 
acid residues involved in selective agonist binding around ECL- 
I of the ~- and/l-opioid receptor molecules. The results ob- 
tained indicate that 6K108 and ~tN127, corresponding to each 
other in the aligned amino acid sequences, are important in 
defining the difference in DAGO binding affinity between the 
~- and the/.t-receptors. 
Replacement of ~K108, which is positively charged, with a 
positively charged amino acid (6K108R) did not significantly 
affect the binding affinity to DAGO. On the other hand, re- 
placement with a non-charged or negatively charged amino 
acid (~K108N, 6K108A or ~K108D) improved the DAGO 
binding affinity to be comparable with that of the wild-type 
~t-receptor. This result suggests that a positive charge at amino 
acid residue-108 in the ~-receptor determines the low DAGO 
binding affinity of the ~-receptor probably by hindering inter- 
action of DAGO with the agonist binding site, rather than that 
~tN127, corresponding to 6K108, determines the high affinity 
to DAGO of the/~-receptor. The DAGO binding affinity of the 
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x-receptor is as low as that of the d-receptor [18], although the 
amino acid residue-108 in the amino acid sequence of the x- 
receptor, corresponding to dK108 and/tN127, is valine, which 
does not have a positive charge. This may suggest hat the 
amino acid sequence of the x-receptor other than ECL-I plays 
a major role in determining the low DAGO binding affinity of 
the x-receptor. This notion is supported by the recent report 
that DAGO distinguishes between the/t- and x-receptors at the 
region around ECL-III, different from the case of distinction 
between the d- and/t-receptors [12]. 
Replacement o fpG 131 with the corresponding residue in the 
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Fig. 2. Displacement of[3H]EKC binding to the wild-type and mutant 
opioid receptors expressed in COS-7 cells. Membrane was prepared 
from COS-7 cells expressing the wild-type 5- (e) and p- (A) receptors, 
dK108N (©), dK108R (zx), o"K108D (~7), 5K108A (n) andpN127K ( × ). 
Competitive ligand binding assay in the presence of 10 nM [3H]EKC 
and increasing concentrations of unlabeled DAGO (A), DPDPE (B) 
and morphine (C) was performed. Each point represents mean from 3-6 
experiments. Values for 100% and 0% were determined by measure- 
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Fig. 3. Competition binding experiments in the wild-type and mutant 
opioid receptors. Binding affinities to DAGO (A), DPDPE (B) and 
morphine (C) of the wild-type dL (e) and/t- (A) receptors, dE112G (©), 
pG131E (A) and/tG 131A (v) were estimated as described in the legend 
to Fig. 2. Each point represents mean from 3-6 experiments. 
resembling that of the d-receptor. However, dE 112G, the recip- 
rocal mutation of/tG131E, and/tG131A did not significantly 
change the agonist binding property of the 5-receptor and that 
of the p-receptor, espectively. These results together may sug- 
gest that pG131 does not directly interact with agonists but is 
located near the agonist binding site. It might be possible that 
replacement ofpG 131 with glutamic acid, a negatively charged 
amino acid, indirectly changes the local conformation of the 
agonist binding site of the/t-receptor to be similar as that of 
the d-receptor. 
In our previous study on the chimeric receptors [10], the 
major determinants for the difference in binding affinity to 
DPDPE and morphine between the d- and the/t-receptors were 
demonstrated to exist in the region spanning TM-V VII. On 
the other hand, in the present study amino acid replacements 
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Fig. 4. [3H]DAGO binding to the wild-type #-receptor and &K108N. 
Membrane preparations from COS-7 cells expressing the wild-type 
/~-receptor (A) and ~K108N (B) were subjected to saturation analysis 
with [3H]DAGO. The non-specific binding was measured in the pres- 
ence of 10/IM unlabeled DAGO. Results of representative experiments 
are shown. The insets show Scatchard plots of the data. 
in the ECL-I of the ~- and #-receptors produced small changes 
in binding affinities to DPDPE and morphine, suggesting that 
ECL-I of the opioid receptor also partly contributes to forming 
the binding sites for DPDPE and morphine. These observations 
together may imply that the agonist binding site of the opioid 
receptor is constituted from multiple parts of the receptor pol- 
ypeptide. In conjunction with this idea, it has been suggested 
that amino acid residues involved in binding with peptide ag- 
onists are scattered throughout the receptor structure of the 
neurokinin receptor [19,20] and the angiotensin II receptor [21]. 
In conclusion, our results indicate that the one amino acid 
difference in ECL-I in the aligned amino acid sequences (&K108 
and #N127) mainly determines the difference in DAGO bind- 
ing affinity between the ~- and the #-receptors, which is possi- 
bly due to the hindrance of interaction of DAGO with the 
agonist binding site by a positive charge at amino acid residue- 
108 of the 5-receptor, and partly contributes to determining the 
difference in binding affinities to DPDPE and morphine. It was 
further suggested that #GI31 in ECL-I is located near the 
agonist binding site of the #-receptor. These results would pro- 
vide important information to elucidate the structural basis of 
the ligand selectivity of the opioid receptor, and would facilitate 
development of highly selective opioid analgesics, which might 
have side effects less than opioids currently used and might be 
useful to clarify the physiological roles of individual opioid 
receptor types. 
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